Latest News

RTI Surgical Inc. Announces $15 Million Innovation Enhancement Project

Amelia Bell
Media Contact

RTI Surgical Inc. Announces $15 Million Innovation Enhancement Project
Project will increase tissue sterilization capacity to help more patients

ALACHUA, Fla., April 14, 2022 - Today, RTI Surgical announced a $15 million innovation enhancement project to augment tissue processing capacity at its Alachua, Fla. facility. As an industry-leading private label OEM supplier of allograft, xenograft and synthetic-based surgical implants, RTI partners with leading medical technology companies around the world to provide outsourced private label design, development, processing, manufacturing and life cycle management services.

The project, which begins in May 2022, involves the expansion and enhancement of more than 5,000 square feet of custom-designed clean rooms to accommodate the significant growth in customer demand for implants processed through the company’s proprietary Tutoplast® Tissue Sterilization Process. The project is expected to take 18 to 24 months.

“We are honored to process tissue into high-quality surgical implants that improve the lives of millions of patients around the world. This project will increase our processing capacity, enabling us to maximize the gift of tissue donation and improve the quality of life for more patients,” said Olivier Visa, President and Chief Executive Officer.

The Tutoplast® Process is a chemical sterilization methodology originally developed more than 50 years ago by Tutogen Medical to preserve and sterilize tissue for implantation. RTI and Tutogen merged in 2008. Bone implants, membranes and other soft tissue grafts sterilized through the Tutoplast Process are used in a variety of clinical applications, including dental, plastic & reconstructive surgery, urology/urogynecology, wound care and ophthalmology. On average, more than 500,000 patients receive implants processed through the Tutoplast Process each year.

About RTI Surgical
RTI Surgical (RTI) is a global, industry-leading private label OEM that provides design, new product development, processing, and manufacturing services in support of patients and leading medical technology companies. With expertise in allograft and xenograft tissue-based implants RTI serves partners across a diverse set of market segments, including but not limited to, Dental, Plastic & Reconstructive Surgery, Sports Medicine, Spine, Trauma and Urology/Urogynecology. RTI is headquartered in Alachua, Fla., and has three manufacturing facilities throughout the United States and Europe. The company is accredited in the U.S. by the American Association of Tissue Banks. For more information, visit